布罗达单抗在三名银屑病合并精神疾病患者中的应用。
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities.
作者信息
Rivera-Oyola Ryan, Stanger Roselyn, Litchman Graham H, Thibodeaux Quinn, Koo John, Fried Richard, Goldenberg Gary, Han George, Hsu Sylvia, Kircik Leon, Knuckles Melissa, Murina Andrea, Weinberg Jeffrey, Wu Jashin J, Lebwohl Mark
机构信息
Mr. Rivera-Oyola and Drs. Stanger, Goldenberg, Han, Kircik, Weinberg, and Lebwohl are with the Icahn School of Medicine at Mt. Sinai Hospital in the Department of Dermatology in New York, New York.
Dr. Litchman is with the National Society for Cutaneous Medicine in New York, New York.
出版信息
J Clin Aesthet Dermatol. 2020 Dec;13(12):44-48. Epub 2020 Dec 1.
Brodalumab, a first-in-class interleukin-17 (IL-17) receptor blocker, carries a black box warning for suicidal ideation and behavior, yet it is also one of the most powerful biologic agents in our armamentarium. We wish to highlight three patients with moderate-to-severe psoriasis and comorbid depression who were successfully treated with brodalumab. The patients were chosen by an expert panel comprising dermatologists, psychiatrists, and psychologists. Psoriasis disease severity was measured using the Psoriasis Area and Severity Index (PASI) score. All three patients experienced PASI 100 after treatment with brodalumab (N=3). Importantly, depressive symptoms improved or resolved in two out of three patients. One patient, who had a history of psychiatric hospitalizations, required in-patient psychiatric treatment during treatment. The use of brodalumab in patients with psoriasis can provide rapid-onset improvement in both skin and depressive symptoms.
布罗达单抗是首个白细胞介素-17（IL-17）受体阻滞剂，带有自杀观念和行为的黑框警告，但它也是我们现有药物中最有效的生物制剂之一。我们希望强调三位中度至重度银屑病合并抑郁症患者，他们接受布罗达单抗治疗取得了成功。这些患者由皮肤科医生、精神科医生和心理学家组成的专家小组挑选。银屑病疾病严重程度采用银屑病面积和严重程度指数（PASI）评分来衡量。三位患者接受布罗达单抗治疗后均达到PASI 100（N = 3）。重要的是，三位患者中有两位的抑郁症状得到改善或缓解。一位有精神病住院史的患者在治疗期间需要住院接受精神科治疗。布罗达单抗用于银屑病患者可使皮肤症状和抑郁症状迅速改善。
Zotero 插件